Monoisotopic mass 607
Cumulatively, 569 patients were treated with Montelukast Sodium for at least 6 months
Among all criteria, dissolution profile acceptance is one of the main and major issues
36(1) [Jan
This paper will describe the pharmacology, safety, efficacy and tolerability of montelukast
Montelukast possesses high permeability, but low solubility and therefore, it is categorized as a class II compound in the biopharmaceutics classification system
A novel nanocrystal system of montelukast (MTK) was designed to improve the transdermal delivery, while ensuring chemical stability of the labile compound
5 in blank buffers, but Montelukast is a cysteinyl leukotriene 1 (CysLT 1) receptor antagonist (IC 50 = 4
Montelukast having solubility in Purified water is 4
Hence to achieve such discrimating profile using in vitro dissolution apparatus , one needs to verify the effect of change in the dissolution Determination of the solubility profile: Montelukast potassium is freely soluble in water, soluble in DMSO and slightly soluble in the common organic solvent like ethanol
To achieve the target plasma concentration–time profile observed in adults, montelukast dissolution would need to reach 80 to 100% dissolved within the Continuous improvement of pediatric PBPK models and in vitro age-related solubility/dissolution methods with high-quality physiological and clinical data is essential and will allow For maximum solubility in aqueous buffers, montelukast (sodium salt) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice
Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening Solubility of montelukast was generally lower in drinks than in soft foods, except the case of ‘milky’ drinks and Coca-Cola (Fig
8), which is likely Montelukast sodium (MLK) is a worldwide antiasthmatic drug
For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6–14 years as a 5-mg chewable tablet, and to children aged 2–5 years as a 4-mg chewable tablet form